Editorial theme | Defining steroid- and ruxolitinib-refractory acute and chronic GvHD

Defining SR-GvHD is challenging and half of patients with acute GvHD (aGvHD) will not respond to corticosteroids...

Is combination ATG + PTCy prophylaxis always preferable to using each agent separately in haplo-HCT?

During the 49th Annual Meeting of the EBMT, the GvHD Hub was pleased to speak to Abdul-Hamid...

Fecal microbiota transplantation in high-risk lower GI acute GvHD after allo-HCT

At the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), DeFilipp presented on...

What is the latest data from REACH-3 for ruxolitinib treated patients with SR-cGvHD after crossover?

During the 49th Annual Meeting of the EBMT, the GvHD Hub was pleased to speak to Robert Zeiser,...

Is the novel JAK/ROCK inhibitor TQ05105 effective for patients with SR/SD cGvHD?

During the 2023 European Hematology Association (EHA) Annual Congress, the GvHD hub was pleased to speak with Yanmin...

EHA 2023

Catch up with our live Twitter coverage from the European Hematology Association (EHA) Hybrid Congress, 2023.

Is vedolizumab effective for preventing lower GI acute GvHD?

During the 2023 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, the GvHD Hub was pleased to speak to Yi-Bin Chen,...

GvHD prophylaxis with abatacept in mismatched unrelated donor HCT

Addition of abatacept to standard immunoprophylaxis can improve GvHD related transplant outcomes in mismatched unrelated donor HCT...

Immunosuppressive efficacy and safety of MSCs bioengineered with chimeric antigen receptor (CAR) in GvHD preclinical models

Sirpilla et al. applied chimeric antigen receptor (CAR) technology to MSCs...

Visual abstract | Vitamin A for the prevention of GvHD in pediatric patients undergoing allo-HSCT

Here, we present data from a trial evaluating the efficacy of high-dose vitamin A in preventing GvHD...